Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)
Year: 2022
Type: article
Abstract: BACKGROUND: Histological characteristics at the invasive front may reflect tumor aggressiveness; specifically, tumor budding (Bd) is an emerging prognostic biomarker in colon cancer (CC). We explored further the significance of Bd for risk stratification by evaluating survival of stage III CC patients included in the IDEA-France phase III trial. PATIENTS AND METHODS: ), Bd2 (5-9 buds), and Bd3 (≥10 buds) categories. Disease-free survival (DFS) and overall survival (OS) were analyzed by the log-rank test. Clinicopathological features and Immunoscore® were correlated with Bd. RESULTS: Overall, Bd1, Bd2, and Bd3 were observed in 39%, 28%, and 33% of CC, respectively. Bd2 and Bd3 were associated with vascular (P = 0.002) and perineural invasions (P = 0.0009). The 3-year DFS and the 5-year OS rates for Bd (1 versus 2-3) were 79.4% versus 67.2% (P = 0.001) and 89.2% versus 80.8% (P = 0.001), respectively. This was confirmed after adjustment for relevant clinicopathological features for DFS [hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.12-1.77, P = 0.003] and OS (HR 1.65, 95% CI 1.22-2.22, P = 0.001). When combined with pTN stage and Immunoscore® subgroups, Bd significantly improved disease prognostication. CONCLUSIONS: Bd demonstrated its independent prognostic value for DFS and OS. Given these findings, Bd as per the ITBCC 2016 should be mandatory in every pathology report in stage III CC patients. Bd and Immunoscore® could play a complementary role in personalized health care in this setting.
Source: Annals of Oncology
Institutions: University of Udine, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Université Paris Descartes, Azienda ULSS 8 Berica, Université de Versailles Saint-Quentin-en-Yvelines, Hôpital Ambroise-Paré, Inserm, Methodology and Quality of Life Unit in Oncology, Université Bourgogne Franche-Comté, Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, Institut Sainte Catherine, Centre Hospitalier Universitaire de Nantes, Institute Mutualiste Montsouris, Hôpital Privé Jean Mermo, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne, Centre Georges François Leclerc, Centre de recherche Translationnelle en Médecine moléculaire, Sorbonne Université, Hôpital Saint-Antoine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,230
Awards: G1448824031, G8588254769
OpenAlex ID: W4220689866